Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18763598 | 0.84 | GABRA1 (0.58) | — | |
| SCHEMBL30147378 | 0.83 | CA2 (0.47) | CA2GAAKDM4EATMALDH1A1 | |
| SCHEMBL3782409 | 0.83 | CA2 (0.47) | CA2GAAKDM4EATMALDH1A1 | |
| SCHEMBL11654118 | 0.83 | ALDH1A1 (0.33) | CA2ALOX15PKMALDH1A1HTR2A | |
| SCHEMBL1080853 | 0.83 | CA2 (0.68) | CA2KDM4EATMALDH1A1PPARG | |
| SCHEMBL29559892 | 0.83 | CA2 (0.68) | CA2KDM4EATMALDH1A1PPARG | |
| SCHEMBL17223734 | 0.82 | CA2 (0.39) | CA2ALOX15PKMGAAALOX12 | |
| SCHEMBL7489270 | 0.82 | PKM (0.45) | CA2ALOX15PKMALDH1A1MEN1 | |
| SCHEMBL1799268 | 0.81 | GAA (0.64) | ALOX15PKMGAAKDM4EALDH1A1 | |
| SCHEMBL5465227 | 0.79 | HSD17B10 (0.46) | ALOX15PKMGAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980925-B2 | Antimicrobial amphiphiles and methods for their use | JAMES MADISON INNOVATIONS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140148487-A1 | ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE | James Madison Innovations, Inc, (US) | 2014-05-29 | — | — | US | disclosed |
| WO-2012054695-A1 | NTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE | JAMES MADISON INNOVATIONS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-3947471-A | CHROMOGENIC | SUMITOMO CHEMICAL COMPANY, LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148487-A1 | ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE | ANXA5, ANXA4, ANXA6 | CA2 3241/4885ALOX15 1255/4885PKM 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.